Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 12/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 11/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12024786 | 0.89 | HCRTR1 (0.54) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL13443055 | 0.86 | HCRTR1 (0.57) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL12024774 | 0.81 | PDE2A (0.49) | HCRTR2HCRTR1 | |
| SCHEMBL12391555 | 0.78 | HTT (0.54) | HCRTR2HCRTR1 | |
| SCHEMBL12024791 | 0.78 | HCRTR1 (0.55) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL10134750 | 0.77 | HCRTR1 (0.50) | HCRTR2HCRTR1 | |
| SCHEMBL12391550 | 0.75 | MKNK1 (0.54) | — | |
| SCHEMBL12359372 | 0.74 | HTT (0.53) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL12359369 | 0.74 | CYP2A6 (0.47) | CYP3A4CYP2A6 | |
| SCHEMBL13443057 | 0.74 | HCRTR1 (0.67) | HCRTR2HCRTR1HTR1AOPRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349872-B2 | Tripyridyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885HCRTR1 2/4885CYP3A4 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.